INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., is a pioneering healthcare services company headquartered in Sarasota, Florida. Founded in 2007, the company has dedicated its mission to democratizing access to fertility care by integrating advanced medical technology with patient-centric clinical services. Following its rebranding in April 2025, the company has strategically positioned itself at the intersection of reproductive medicine and biotechnology, aiming to address the growing global demand for accessible and effective fertility solutions while simultaneously expanding its footprint into specialized therapeutic development.
The company’s operational framework is divided into three core segments: Fertility Clinic Services, the proprietary INVOcell Device, and Therapeutics. The flagship INVOcell device represents a significant technological breakthrough in assisted reproductive technology (ART). Unlike traditional in vitro fertilization (IVF) methods that rely on laboratory incubators, the INVOcell device facilitates fertilization and early embryo development in vivo, directly within the woman’s body. This innovative approach not only reduces the reliance on expensive laboratory infrastructure but also offers a more natural and cost-effective alternative for patients. Furthermore, the company is diversifying its portfolio through its Therapeutics segment, which includes the development of NY-303, a GPC3 x NKp46 bifunctional antibody currently in Phase I/IIa trials for hepatocellular carcinoma, and NY-500, an AI-optimized antibody platform.
INVO Fertility maintains a robust market position by operating a network of fertility clinics, known as INVO Centers, which serve as the primary delivery points for its proprietary technology. By controlling both the clinical delivery and the underlying medical device technology, the company effectively captures value across the entire fertility care continuum. Its target demographic includes couples and individuals facing infertility who seek more affordable, accessible, and less invasive options compared to conventional IVF. With a focus on both domestic expansion and potential international scaling, the company is leveraging its unique clinical model to penetrate underserved segments of the fertility market.
Looking toward the future, INVO Fertility is focused on a dual-growth strategy that balances its established fertility services with high-potential biopharmaceutical innovation. The strategic pivot toward oncology therapeutics, specifically through its bifunctional antibody pipeline, signals a long-term commitment to high-growth medical sectors. By integrating AI-driven drug discovery with its proven fertility business model, the company aims to enhance shareholder value and improve patient outcomes. As the company continues to refine its clinical operations and advance its clinical-stage drug candidates, it remains well-positioned to capitalize on the increasing global emphasis on reproductive health and precision medicine.
Economic Moat
The company possesses a significant competitive advantage through its proprietary INVOcell device, which is protected by intellectual property and offers a unique, cost-effective, and less invasive alternative to traditional IVF. Furthermore, its vertically integrated model, which combines specialized clinical services with internal medical device production, creates high barriers to entry for competitors who lack this dual-capability infrastructure.